deltatrials
Recruiting NA Interventional 1-arm NCT02559544

[18F]Fluoroestradiol (FES) PET/CT Imaging to Evaluate in Vivo Estrogen Receptor Activity in Endocrine Refractory Recurrent or Metastatic Breast Cancer

Sponsor: Abramson Cancer Center of the University of Pennsylvania

Conditions Metastatic ER+ Breast Cancer Recurrent ER+ Breast Cancer
Interventions [18F]Fluoroestradiol (FES) PET/CT Imaging
Updated 4 times since 2017 Last updated: Sep 27, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Metastatic ER+ Breast Cancer and Recurrent ER+ Breast Cancer, this trial is actively recruiting participants. The trial is conducted by Abramson Cancer Center of the University of Pennsylvania and has accumulated 4 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotRecruiting~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotRecruiting~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshotRecruiting~Oct 2018 – present · 93 months · monthly snapshotRecruiting

Change History

4 versions recorded

  1. Oct 2018 — Present [monthly]

    Recruiting NA

  2. Jun 2018 — Oct 2018 [monthly]

    Recruiting NA

  3. Feb 2017 — Jun 2018 [monthly]

    Recruiting NA

    Phase: Phase 0 → NA

  4. Jan 2017 — Feb 2017 [monthly]

    Recruiting Phase 0

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Abramson Cancer Center of the University of Pennsylvania
Data source: Abramson Cancer Center of the University of Pennsylvania

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations